These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21229233)

  • 1. Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Osteoporos Int; 2011 Mar; 22(3):809-16. PubMed ID: 21229233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment.
    Leslie WD; Lix LM; Langsetmo L; Berger C; Goltzman D; Hanley DA; Adachi JD; Johansson H; Oden A; McCloskey E; Kanis JA
    Osteoporos Int; 2011 Mar; 22(3):817-27. PubMed ID: 21161509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of a FRAX revision for the USA.
    Kanis JA; Johansson H; Oden A; Dawson-Hughes B; Melton LJ; McCloskey EV
    Osteoporos Int; 2010 Jan; 21(1):35-40. PubMed ID: 19705047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.
    Fraser LA; Langsetmo L; Berger C; Ioannidis G; Goltzman D; Adachi JD; Papaioannou A; Josse R; Kovacs CS; Olszynski WP; Towheed T; Hanley DA; Kaiser SM; Prior J; Jamal S; Kreiger N; Brown JP; Johansson H; Oden A; McCloskey E; Kanis JA; Leslie WD;
    Osteoporos Int; 2011 Mar; 22(3):829-37. PubMed ID: 21161508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fracture risk prediction using FRAX®: a 10-year follow-up survey of the Japanese Population-Based Osteoporosis (JPOS) Cohort Study.
    Tamaki J; Iki M; Kadowaki E; Sato Y; Kajita E; Kagamimori S; Kagawa Y; Yoneshima H
    Osteoporos Int; 2011 Dec; 22(12):3037-45. PubMed ID: 21279504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures.
    Lalmohamed A; Welsing PM; Lems WF; Jacobs JW; Kanis JA; Johansson H; De Boer A; De Vries F
    Osteoporos Int; 2012 Mar; 23(3):861-9. PubMed ID: 22120910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjusting conventional FRAX estimates of fracture probability according to the number of prior fractures.
    Kanis JA; Johansson H; Harvey NC; Gudnason V; Sigurdsson G; Siggeirsdottir K; Lorentzon M; Liu E; Vandenput L; McCloskey EV
    Osteoporos Int; 2022 Dec; 33(12):2507-2515. PubMed ID: 36161339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement.
    Leslie WD; Lix LM; Johansson H; Oden A; McCloskey E; Kanis JA
    Osteoporos Int; 2011 Mar; 22(3):839-47. PubMed ID: 20959961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FRAX® probabilities and risk of major osteoporotic fracture in France.
    Couris CM; Chapurlat RD; Kanis JA; Johansson H; Burlet N; Delmas PD; Schott AM
    Osteoporos Int; 2012 Sep; 23(9):2321-7. PubMed ID: 22179418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FRAX-based Estimates of 10-year Probability of Hip and Major Osteoporotic Fracture Among Adults Aged 40 and Over: United States, 2013 and 2014.
    Looker AC; Sarafrazi Isfahani N; Fan B; Shepherd JA
    Natl Health Stat Report; 2017 Mar; (103):1-16. PubMed ID: 28459415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study.
    Ettinger B; Ensrud KE; Blackwell T; Curtis JR; Lapidus JA; Orwoll ES;
    Osteoporos Int; 2013 Apr; 24(4):1185-93. PubMed ID: 23179575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of FRAX to characterise fracture risk in Poland.
    Czerwinski E; Kanis JA; Osieleniec J; Kumorek A; Milert A; Johansson H; McCloskey EV; Gorkiewicz M
    Osteoporos Int; 2011 Sep; 22(9):2507-12. PubMed ID: 21127840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjusting conventional FRAX estimates of fracture probability according to the number of prior falls in the preceding year.
    Kanis JA; Johansson H; Harvey NC; Lorentzon M; Liu E; Vandenput L; Morin S; Leslie WD; McCloskey EV
    Osteoporos Int; 2023 Mar; 34(3):479-487. PubMed ID: 36562788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Fracture Risk Assessment Tool in clinical practice and Fracture Risk Assessment Tool future directions.
    Zerikly R; Demetriou EW
    Womens Health (Lond); 2024; 20():17455057241231387. PubMed ID: 38529935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®).
    Leib ES; Saag KG; Adachi JD; Geusens PP; Binkley N; McCloskey EV; Hans DB;
    J Clin Densitom; 2011; 14(3):212-9. PubMed ID: 21810527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture Risk Indices From DXA-Based Finite Element Analysis Predict Incident Fractures Independently From FRAX: The Manitoba BMD Registry.
    Leslie WD; Luo Y; Yang S; Goertzen AL; Ahmed S; Delubac I; Lix LM
    J Clin Densitom; 2019; 22(3):338-345. PubMed ID: 30852033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density.
    Klop C; de Vries F; Bijlsma JW; Leufkens HG; Welsing PM
    Ann Rheum Dis; 2016 Dec; 75(12):2095-2100. PubMed ID: 26984006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of hip fracture and the development of FRAX in Ukraine.
    Povoroznyuk VV; Grygorieva NV; Kanis JA; Ev M; Johansson H; Harvey NC; Korzh MO; Strafun SS; Vaida VM; Klymovytsky FV; Vlasenko RO; Forosenko VS
    Arch Osteoporos; 2017 Dec; 12(1):53. PubMed ID: 28567714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.
    Kanis JA; McCloskey EV; Johansson H; Strom O; Borgstrom F; Oden A;
    Osteoporos Int; 2008 Oct; 19(10):1395-408. PubMed ID: 18751937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FRAX-based intervention and assessment thresholds for osteoporosis in Iran.
    Khashayar P; Keshtkar A; Ostovar A; Larijani B; Johansson H; Harvey NC; Lorentzon M; McCloskey E; Kanis JA
    Osteoporos Int; 2019 Nov; 30(11):2225-2230. PubMed ID: 31372709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.